PeptideDB

C6 NBD Galactosylceramide

CAS: 170212-26-7 F: C36H59N5O11 W: 737.88

C6 NBD galactosylceramide is an active derivative of galactosylceramide that is tagged with fluorescent C6 nitrobenzoxad
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity C6 NBD galactosylceramide is an active derivative of galactosylceramide that is tagged with fluorescent C6 nitrobenzoxadiazole (C6 NBD). C6 NBD galactosylceramide can be used as a substrate for neutral β-glycosylceramidase (GCase) to study intracellular localization and metabolism of galactosylceramide (Ex=nm, Em=525)[1]. Storage: protect from light.
Invitro C6-NBD-glucosylceramide (4 μM) is transported to the Golgi apparatus in HT29 cells[1].Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs)[2].Transcytosis of Exogenous C6-NBD-GaICer after Endocytosis: 1. C6-NBD-glucosylceramide is inserted at 10°C. 2. Cells are rinsed three times with cold HBSS' and incubated at 37°C in HBSS' to allow endocytosis. 3. After 10 min, the probe remaining on the cell surface is removed by two (apical) or three (basal) BSA washes for 20 min at 10°C. 4. One set of filters is used for lipid analysis to quantitate endocytosis. A second set of filters is further incubated for 0.5 or 1 h at 37°C in HBSS' + BSA, to assay for reappearance of intracellular C6-NBD-glucosylceramide on either cell surface. 5. The incubations are followed by a 10°C BSA wash, after which the NBD lipids from the combined apical media, basal media, and the cells were extracted into chloroform/methanol, analyzed by TLC, and quantitated.
Name C6 NBD Galactosylceramide
CAS 170212-26-7
Formula C36H59N5O11
Molar Mass 737.88
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. J W Kok, et al. Sorting of sphingolipids in the endocytic pathway of HT29 cells. J Cell Biol. 1991 Jul;114(2):231-9. [2]. I van Genderen, et al. Differential targeting of glucosylceramide and galactosylceramide analogues after synthesis but not during transcytosis in Madin-Darby canine kidney cells. J Cell Biol. 1995 Nov;131(3):645-54.